Cancer immunity
Journal
Overview
publication venue for
-
Chromosome X-encoded Cancer/Testis antigens are less frequently expressed in non-seminomatous germ cell tumors than in seminomas..
13.
2013
-
Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma..
13.
2013
-
The journey from autologous typing to SEREX, NY-ESO-1, and cancer/testis antigens..
12.
2012
-
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials..
10.
2010
-
Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients..
10.
2010
-
Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma..
9.
2009
-
PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses..
7.
2007
-
Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors..
7.
2007
-
Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6)..
6.
2006
-
Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma..
6.
2006
-
Generation of monoclonal antibodies to cancer/testis (CT) antigen CT10/MAGE-C2..
6.
2006
-
Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes..
5.
2005
-
Identification of CT46/HORMAD1, an immunogenic cancer/testis antigen encoding a putative meiosis-related protein..
5.
2005
-
Antigens recognized by autologous antibodies of patients with soft tissue sarcoma..
5.
2005
-
Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics..
5.
2005
-
HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones..
4.
2004
-
Identification of the gonad-specific anion transporter SLCO6A1 as a cancer/testis (CT) antigen expressed in human lung cancer..
4.
2004
-
Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer..
4.
2004
-
The humoral immune response to head and neck cancer antigens as defined by the serological analysis of tumor antigens by recombinant cDNA expression cloning..
4.
2004
-
Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer..
3.
2003
-
SSX antigens as tumor vaccine targets in human sarcoma..
3.
2003
-
NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer..
3.
2003
-
Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease..
3.
2003
-
Expression of cancer-testis genes in human hepatocellular carcinomas..
2.
2002
-
Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51..
2.
2002
-
Urine antibody against human cancer antigen NY-ESO-1..
2.
2002
-
Induction of autoantibodies against tyrosinase-related proteins following DNA vaccination: unexpected reactivity to a protein paralogue..
2.
2002
-
Identification of tumor-restricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum..
2.
2002
-
Alternative roles for interferon-gamma in the immune response to DNA vaccines encoding related melanosomal antigens..
1.
2001
-
Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression..
1.
2001
Identity
ISO Abbreviation
Linking ISSN
Electronic International Standard Serial Number (EISSN)